(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2015 (15.10.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/157238 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2015/024650

(22) International Filing Date:
7 April 2015 (07.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/976,684 8 April 2014 (08.04.2014) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(71) Applicants : **ETTINGER, Catherine** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **KARNELL, Jodi** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DAMSCHRODER, Melissa** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **CHOWDHURY, Partha** [IN/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **XIAO, Xiaodong** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **TSUI, Ping** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **VARKEY, Reena** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DRABIC, Stacey** [US/US]; c/o Medlmmune, LLC, One

[Continued on next page]

(54) Title: BINDING MOLECULES SPECIFIC FOR IL-21 AND USES THEREOF





FIG. 1A

FIG. 1A Contd.

FIG. 1B



FIG. 1B Contd.



(57) Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21 -mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

WO 2015/157238 A2

Medlmmune Way, Gaithersburg, MD 20878 (US). **CARTER, Laura** [US/US]; 2687 Georgetown Blvd., Ann Arbor, MI 48105 (US). **HERBST, Ronald** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **DU, Qun** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **NAIMAN, Brian, Michael** [US/US]; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US).

(74) **Agents**: **OYLOE, Jacob** et al.; Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*